首页> 外国专利> Diaminopirimidinas as modulators of P2X3 and P2X2 / 3, Pharmaceutical compositions that comprise and use in preparation of drugs for the treatment of related diseases.

Diaminopirimidinas as modulators of P2X3 and P2X2 / 3, Pharmaceutical compositions that comprise and use in preparation of drugs for the treatment of related diseases.

机译:作为P2X3和P2X2 / 3调节剂的二氨基嘧啶,包含和用于制备治疗相关疾病的药物的药物组合物。

摘要

Also provided are medicines that use compounds for treating Diseases mediated by P2X3 Receptor Antagonists P P2X2 / 3 and Pharmaceutical compositions containing same.Claim 1: a compound of the formula (1) or a pharmaceutically acceptable Salt thereof, in which X is - CH2 -, - O -, - S (o) n -, o - NRC; where n is 0 to 2 and RC is H or alkyl; d is a or Optional; one or two of a, e, G, J, y, and Z are n while others are CRA; or a, e, G, J, and C and Z are Ra; r1 is alkyl, cycloalkyl, alquenilo, alquinilo, cicloalquenilo, Halo, haloalquilo,Or hidroxialquilo independently; each ra is H, alkyl, amino, alquenilo, aminosulfonilo, Halo, haloalquilo, amido, Hydroxy, alkoxy, Nitro, amino, haloalcoxi, hidroxialquilo, alkoxyalkyl esters, hidroxialcoxi, alquinilalcoxi, alquilsulfonilo, arilsulfonilo, cyano, aryl, heteroaryl, heterociclilo, Heterociclilalcoxi, ariloxi, heteroariloxi, aralquiloxi, heteroaralquiloxi,Optionally substituted phenoxy; c:: C - RB -; - (CH2) M - (Z) - N - (CO) RC; - (CH2) M - (Z) - SO2 - (NRD) n - RC, where M and N are each independently 0 OR 1 Z is o or NRD, rb is H, alkyl, aryl, heteroaryl, aralquilo, heteroaralquilo, hidroxialquilo, alkoxyalkyl esters, alquilsulfonilalquilo, aminoalquilo, C Ianoalquilo, alquilsililo, cycloalkyl, cicloalquilalquilo,And heterociclilalquilo; heterocycle; RC is H, alkyl, Hydroxy, alkoxy, amino, or alkoxyalkyl Esters hidroxialquilo Rd, and each is independently H or alkyl; R4 is H, alkyl, Halo, haloalquilo, amino, or alkoxy; R7 and R8 each independently is H, alkyl, cycloalkyl, cicloalquilalquilo, Haloa Lquilo, haloalcoxi, hidroxialquilo alkoxyalkyl esters, alquilsulfonilo alquilsulfonilalquilo,,,Aminocarboniloxialquilo, hidroxicarbonilalquilo, hidroxialquiloxicarbonilalquilo, aryl, heteroaryl, aralquilo, arilsulfonilo, heteroarilalquilo, heteroarilsulfonilo, heterociclilo, heterociclilalquilo; o - (c = o) - Re, in which re is alkyl, alkoxy, cycloalkyl, cicloalcoxi, cicloalquilalquilo CIC Loalquilalcoxi, aryl, heteroaryl, ariloxi, heteroariloxi, aralquilo, aralcoxi, heteroaralquilo,Heteroaralcoxi, - (CH2) P - C (= o) - (RF - ch = CH -) - C (= o) - RF, or - ch (NH2) - RG, which RF is H, alkyl, Hydroxy, alkoxy, cicloalcoxi, cycloalkyl, aryl, cicloalquilalquilo, cicloalquilalcoxi, ariloxi, heteroaryl, heteroariloxi, aralquilo, aralcoxi, heteroaralquilo, heteroaralcoxi or amino; p is 2 or 3; RG is H, alkyl, optionally substituted hidroxialquilo, aminoalquilo, phenyl, Benzyl,Guanidinilalquilo, carboxialquilo, amidoalquilo, tioalquilo or imidazolalquilo.
机译:还提供了使用化合物来治疗由P2X3受体拮抗剂P P2X2 / 3介导的疾病的药物和包含该化合物的药物组合物。权利要求1:式(1)的化合物或其药学上可接受的盐,其中X是-CH 2 -,-O-,-S(o)n-,o-NRC;其中n为0至2且RC为H或烷基; d是a或Optional; a,e,G,J,y和Z中的一个或两个为n,而其他为CRA; a,e,G,J和C和Z为Ra; r1分别为烷基,环烷基,alquenilo,alquinilo,cicloalquenilo,Halo,卤代alquilo或hidroxialquilo;每个ra是H,烷基,氨基,烷基,氨基磺酰基,卤素,卤代基洛基,酰胺基,羟基,烷氧基,硝基,氨基,卤代alcoxi,羟基代基洛基,烷氧基烷基酯,羟基代昔洛基,喹啉基亚基,烷基磺基,芳基砜基,杂基杂菌素,阿里洛西,杂阿里洛西,阿拉拉基西,杂芳基拉基西,任选取代的苯氧基; c :: C-RB-; -(CH2)M-(Z)-N-(CO)RC; -(CH 2)M-(Z)-SO 2-(NRD)n-RC,其中M和N各自独立为0或1 Z为o或NRD,rb为H,烷基,芳基,杂芳基,芳基,杂芳基,广醛基,烷氧基烷基酯,亚磺酰基alquilo,氨基alquilo,C Ianoalquilo,alquilsililo,环烷基,cicloalquilalquilo和heterociclilalquilo;杂环RC是H,烷基,羟基,烷氧基,氨基或烷氧基烷基Esters hidroxialquilo Rd,并且各自独立地是H或烷基; R4为H,烷基,卤素,卤代烷基,氨基或烷氧基; R 7和R 8各自独立地为H,烷基,环烷基,环氯代喹啉基,Haloa Lquilo,卤代烷氧基,羟基代喹啉烷氧基烷基酯,alquilsulfonilo Alquilsulfonilalquilolo 、、、氨基碳基杂环基,杂芳基,杂环基,杂芳基,杂芳基,杂芳基,杂芳基,杂芳基,杂芳基,杂芳基,杂芳基,杂芳基,杂芳基,杂芳基,杂芳基,杂芳基,杂芳基,杂芳基,杂芳基o-(c = o)-Re,其中re是烷基,烷氧基,环烷基,环氯苯氧基,环氯喹啉基CIC Loalquilalcoxi,芳基,杂芳基,芳基,杂芳基,阿拉尔基洛,阿拉尔基,杂芳基,杂芳基,-(CH2)P-C( = o)-(RF-ch = CH-)-C(= o)-RF或-ch(NH2)-RG,其中RF为H,烷基,羟基,烷氧基,环氯噻吩,环烷基,芳基,环氯代喹啉基,环氯代喹啉,芳基,杂芳基,芳基,芳基,芳基,杂芳基,杂芳基或氨基; p是2或3; RG为H,烷基,任选取代的羟喹啉基,氨基喹啉基,苯基,苄基,Guanidinilalquilo基,羧喹啉基,酰胺基喹啉基,噻吩并基或咪唑并吡咯基。

著录项

  • 公开/公告号AR055618A1

    专利类型

  • 公开/公告日2007-08-29

    原文格式PDF

  • 申请/专利权人 F. HOFFMANN-LA ROCHE AG;

    申请/专利号AR2006P103782

  • 发明设计人

    申请日2006-08-30

  • 分类号C07D239/48;C07D401/12;C07D403/12;C07D471/04;A61K31/506;A61P13/00;

  • 国家 AR

  • 入库时间 2022-08-21 20:59:35

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号